Prostate cancer
Conditions
Interventions
Intervention Experimental Group (group A): You will receive doxycycline 100 mg every 24 hours for 6 months, plus its standard treatment, which consists of bicalutamide 50 mg orally per day, and leupro
Doxycycline
Leuprolide
Tablets
Placebos
Administration, Oral
Injections, Subcutaneous
Bicalutamida
Sponsors
Medical School of the University of Colima, Mexico
Cancerology State Institute, Colima State Health Service (SSA-Colima), Mexico
Mexico Mexican Social Security Institute.
Eligibility
Sex/Gender
Male
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Clinical and histological diagnosis of excised adenocarcinoma, locally advanced and metastatic prostate cancer. 2. Patients who accept, with informed consent, the administration of doxycycline or placebo, in a randomized system
Exclusion criteria
Exclusion criteria: 1. Diagnosis of another primary cancer other than prostate. 2. Alcoholism and / or drug addiction. 3. Allergic to tetracyclines. 4. Gastrointestinal ulcer. 5. Inflammatory bowel disease. 6. Diagnosis of ischemic heart disease. 7. Liver disease. 8. Kidney disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete response (25% reduction in serum specific prostate antigen). Measuring time: 3 and 6 months. | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events (according to the common terminology of criteria for adverse events (CTCAE version 3). Measurement time: every week until month 6. Change in the level of prostate-specific antigen at 6 months of treatment. Quality of life and cognitive impairment were assessed with the EORTC QLQ-PR25 questionnaire and the Mini-Mental State Examination test, respectively, applied at baseline and 6 months after treatment. | — |
Countries
Mexico
Contacts
Public ContactJosé Guzman Esquivel
Mexican Institute of Social Security, General Hospital of Zone 1
Outcome results
None listed